Crystal Adam, the President of Research and Development at Tango Therapeutics, Inc., recently reported several stock transactions that highlight her active role in managing her equity holdings. This activity is particularly noteworthy as it reflects the ongoing engagement of executives in financial markets and may prompt discussions regarding transparency and trading practices within the pharmaceutical industry.

Background

Tango Therapeutics, Inc. operates in the pharmaceutical preparations sector, focusing on innovative treatments. The company is incorporated in Delaware and has its headquarters in Boston, Massachusetts. It trades under the ticker symbol TNGX. The recent filing of a Form 4 on November 4, 2026, details Adam's stock transactions that occurred on November 2, 2026.

What the Filing Says

According to the SEC filing (accession number 0001193125-26-447915), Adam reported multiple transactions involving Tango Therapeutics' common stock. Notably, she acquired 5,000 shares at a price of $2.91 each and disposed of 3,900 shares at an average price of $22.2617. Additionally, she sold another 1,100 shares at an average price of $22.9882. Following these transactions, she holds a total of 115,743 shares directly.

Impact

These transactions may impact various stakeholders, including shareholders and analysts monitoring executive trading patterns. Adam's active trading could raise questions about the timing and motivations behind her decisions, particularly in the context of her role as President of R&D. Furthermore, the pharmaceutical preparations industry may experience heightened scrutiny regarding executive stock transactions, as transparency in trading practices becomes increasingly important.

What's Next

The filing does not say what happens next.